Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance

Inclusion Criteria: * weighing ≥ 10 kg * residing in the area covered by the investigating centre throughout the entire follow-up period * axillary temperature ≥ 37.5 degrees Celsius or history of fever within the previous 24 hours * Plasmodium falciparum density in the blood ranging from 1000 to 100,000 asexual forms per cubic millimetre Exclusion Criteria: * presence of at least one sign of severe malaria or clinical danger sign : prostration, consciousness disorders, recent and repeated convulsions , respiratory distress, inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice, haemorrhagic shock, systolic Blood Pressure \< 70 mmHg in adults or \< 50 in children, spontaneous bleeding, inability to sit or stand * serious concomitant disease * allergy to one of the investigational medicinal products * pregnant women or breast-feeding women. * documented intake of an antimalarial at a suitable dosage within seven days prior to inclusion.